SION
Sionna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.96
−16.99%Sep 16, 2026, 16:31 UTC
Sionna Therapeutics announced it will cut its workforce by 46% after SION-719 failed a key cystic fibrosis study, shifting focus to SION-451 and SION-2222.
Source:Sep 14, 2026, 20:12 UTC
Sionna Therapeutics announced role changes effective September 16, 2026, for Chief Medical Officer Charlotte McKee, Chief Financial Officer Elena Ridloff, and Chief Legal Officer Jennifer Fitzpatrick.
Sep 14, 2026, 20:12 UTC
Sionna Therapeutics terminated Chief Business Officer Caroline Stark Beer effective September 15, 2026, with Elena Ridloff succeeding her.
Sep 14, 2026, 20:01 UTC
Sionna Therapeutics announced plans to advance its SION-451 plus SION-2222 dual combination into a Phase 2a proof-of-concept trial.
Aug 16, 2026, 22:00 UTC
SBS Law announced an investigation into potential securities fraud claims on behalf of Sionna Therapeutics, Inc. investors.
Aug 13, 2026, 02:03 UTC
Robbins Geller Rudman & Dowd LLP announced an investigation into Sionna Therapeutics, Inc. for potential violations of U.S. federal securities laws.
Source:Aug 10, 2026, 12:03 UTC
Sionna Therapeutics announced that its experimental cystic fibrosis pill SION-719 failed to show benefit in a Phase 2 trial when added to Vertex Pharmaceuticals' Trikafta, and the company will not advance it as an add-on therapy.
Aug 10, 2026, 11:13 UTC
SIONNA Therapeutics' stock plunged 87% in pre-market trading after the company released updated data on its primary endpoint.
Aug 6, 2026, 11:00 UTC
Sionna Therapeutics reported its financial results for the second quarter of 2026.
Source: